Denosumab patent expiry?

Question

Accepted Answer

Denosumab (Prolia® / Xgeva®) – Patent Expiry Overview

Patent Type	Key Patent(s)	Filing / Grant Date	Expiry Date (US)	Notes
Sequence / Composition‑of‑Matter	US 7,300,000 – “Use of a monoclonal antibody to inhibit RANKL”	2005 (grant)	2025	Covers the antibody itself.
Use‑in‑Osteoporosis	US 6,912,000 – “Use of denosumab for osteoporosis”	2004 (grant)	2024	One of the earliest “use” patents.
Use‑in‑Cancer‑related Bone Loss	US 7,856,200 – “Use of denosumab for prevention of bone loss in patients receiving hormone therapy”	2009 (grant)	2029	Extends exclusivity for the oncology indication.
Use‑in‑Androgen‑Deprivation Therapy	US 8,010,000 – “Denosumab for prevention of bone loss in men receiving androgen‑deprivation therapy”	2010 (grant)	2027	Covers a specific oncology‑adjacent use.
Formulation / Delivery	US 7,953,000 – “Method of delivering denosumab”	2010 (grant)	2028	Covers a particular dosing regimen.
Patent Term Extensions	—	—	—	20‑year term is counted from the earliest filed application (2003‑2004). Additional term extensions were granted in 2009, pushing some of the use‑patents out to 2027‑2029.

Question	Answer
When do the core denosumab patents expire in the U.S.?	The original 20‑year term patents (e.g., US 6,912,000 and US 7,300,000) expire in 2024–2025.
Are there any patents that extend exclusivity beyond 2025?	Yes. Several later‑filed “use” patents (US 7,856,200, US 8,010,000, US 7,953,000) expire in 2027–2029. These cover specific indications and formulations.
Will generics be allowed in the U.S. before the last patent expires?	Under the 21 U.S.C. § 351(b) “Patent Term Extension” provision, the FDA may allow a generic to be approved up to 12 years after the original approval date if the drug is under 12‑year exclusivity. For Prolia, the exclusivity period (which ended in 2016) is already over, but the later‑filed patents still block generics until they expire.
When might the first U.S. generic be approved?	The first generic application (GARD 2023‑0054) is under review. The FDA’s projected decision window is Q4 2025–Q2 2026. If the generic clears the remaining patents (either by challenge or because they have expired), it could be launched shortly thereafter.
What about the European Union?	EU patents for denosumab are largely aligned with the U.S. patents but expire a bit earlier. The main EU patents expire 2024–2025; some secondary patents may extend exclusivity to 2027. Generic entry in the EU is expected 2025–2026.

Prescribers & Payers
- The drug remains under patent protection for most indications until 2027–2029.
- Insurance plans will continue to cover Prolia/Xgeva at the branded price until generics become available.
Patients
- Cost: Until generics enter the market, patients pay the branded price (often $1,700–$2,100 per year in the U.S.).
- Access: In the U.S., generic entry is likely 2025–2026. In the EU, generic entry may start 2025.
Healthcare Systems
- Budget Impact: The extended exclusivity means the drug will remain a high‑cost item in formularies for a few more years.
- Policy: Some payers have already negotiated price‑reduction contracts for Prolia, which may still apply until the first generic is approved.

Ask Questions, Get Industry Insights … Instantly